Literature DB >> 27106405

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Nathalie L Albert1, Michael Weller1, Bogdana Suchorska1, Norbert Galldiks1, Riccardo Soffietti1, Michelle M Kim1, Christian la Fougère1, Whitney Pope1, Ian Law1, Javier Arbizu1, Marc C Chamberlain1, Michael Vogelbaum1, Ben M Ellingson1, Joerg C Tonn2.   

Abstract

This guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose ((18)F-FDG) and amino acid tracers ((11)C-MET, (18)F-FET, and (18)F-FDOPA). An increasing number of studies have been published on PET imaging in the setting of diagnosis, biopsy, and resection as well radiotherapy planning, treatment monitoring, and response assessment. Recommendations are based on evidence generated from studies which validated PET findings by histology or clinical course. This guideline emphasizes the clinical value of PET imaging with superiority of amino acid PET over glucose PET and provides a framework for the use of PET to assist in the management of patients with gliomas.
© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  PET imaging; amino acid PET; glioma; guideline; recommendations

Mesh:

Substances:

Year:  2016        PMID: 27106405      PMCID: PMC4999003          DOI: 10.1093/neuonc/now058

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  120 in total

1.  Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.

Authors:  Madhavi Tripathi; Rajnish Sharma; Maria D'Souza; Abhinav Jaimini; Puja Panwar; Raunak Varshney; Anupama Datta; Nitin Kumar; Gunjan Garg; Dinesh Singh; Rajesh K Grover; Anil K Mishra; Anupam Mondal
Journal:  Clin Nucl Med       Date:  2009-12       Impact factor: 7.794

Review 2.  Value of 11C-methionine PET in imaging brain tumours and metastases.

Authors:  Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-12       Impact factor: 9.236

3.  Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.

Authors:  Lutz W Kracht; Hrvoje Miletic; Susanne Busch; Andreas H Jacobs; Jurgen Voges; Moritz Hoevels; Johannes C Klein; Karl Herholz; Wolf-D Heiss
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

4.  Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence.

Authors:  Christian Ewelt; Frank W Floeth; Jörg Felsberg; Hans J Steiger; Michael Sabel; Karl-Josef Langen; Gabriele Stoffels; Walter Stummer
Journal:  Clin Neurol Neurosurg       Date:  2011-04-20       Impact factor: 1.876

5.  Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.

Authors:  Franziska Walter; Timothy Cloughesy; Martin A Walter; Albert Lai; Phioanh Nghiemphu; Naveed Wagle; Barbara Fueger; Nagichettiar Satyamurthy; Michael E Phelps; Johannes Czernin
Journal:  J Nucl Med       Date:  2012-02-09       Impact factor: 10.057

6.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.

Authors:  Gabriele Pöpperl; Friedrich W Kreth; Jan H Mehrkens; Jochen Herms; Klaus Seelos; Walter Koch; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

7.  The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas.

Authors:  M W Gross; W A Weber; H J Feldmann; P Bartenstein; M Schwaiger; M Molls
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-07-15       Impact factor: 7.038

8.  Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.

Authors:  Norbert Galldiks; Roland Ullrich; Michael Schroeter; Gereon R Fink; Andreas H Jacobs; Lutz W Kracht
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

9.  Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT.

Authors:  Christophe Nioche; Marine Soret; Eric Gontier; Marion Lahutte; Guillaume Dutertre; Renaud Dulou; Laurent Capelle; Rémy Guillevin; Hervé Foehrenbach; Irène Buvat
Journal:  Clin Nucl Med       Date:  2013-02       Impact factor: 7.794

10.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.

Authors:  Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Arlette Vandesteene; Isabelle Salmon; Jacques Brotchi; Marc Levivier
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

View more
  208 in total

Review 1.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

2.  Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.

Authors:  Manuel Röhrich; Kristin Huang; Daniel Schrimpf; Nathalie L Albert; Thomas Hielscher; Andreas von Deimling; Ulrich Schüller; Antonia Dimitrakopoulou-Strauss; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

Review 3.  The Role of Standard and Advanced Imaging for the Management of Brain Malignancies From a Radiation Oncology Standpoint.

Authors:  Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu
Journal:  Neurosurgery       Date:  2019-08-01       Impact factor: 4.654

4.  Hypometabolic gliomas on FET-PET-is there an inverted U-curve for survival?

Authors:  David Olayinka Kamson
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

5.  Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?

Authors:  A Verger; D Taieb; E Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-27       Impact factor: 9.236

6.  Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury.

Authors:  Francesco Cicone; Norbert Galldiks; Giuseppe Minniti; Christian P Filss; Francesco Scopinaro; John O Prior; Nathalie L Albert; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

7.  "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply.

Authors:  Robert J Young; T Jonathan Yang; Vaios Hatzoglou; Gary Ulaner; Antonio Omuro
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

8.  Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.

Authors:  Ramon F Barajas; Bronwyn E Hamilton; Daniel Schwartz; Heather L McConnell; David R Pettersson; Andrea Horvath; Laszlo Szidonya; Csanad G Varallyay; Jenny Firkins; Jerry J Jaboin; Charlotte D Kubicky; Ahmed M Raslan; Aclan Dogan; Justin S Cetas; Jeremy Ciporen; Seunggu J Han; Prakash Ambady; Leslie L Muldoon; Randy Woltjer; William D Rooney; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

9.  Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status.

Authors:  Shuangshuang Song; Leiming Wang; Hongwei Yang; Yongzhi Shan; Ye Cheng; Lixin Xu; Chengyan Dong; Guoguang Zhao; Jie Lu
Journal:  Eur Radiol       Date:  2020-11-19       Impact factor: 5.315

10.  The contribution of ketone bodies to glycolytic inhibition for the treatment of adult and pediatric glioblastoma.

Authors:  Frederic A Vallejo; Sumedh S Shah; Nicolas de Cordoba; Winston M Walters; Jeffrey Prince; Ziad Khatib; Ricardo J Komotar; Steven Vanni; Regina M Graham
Journal:  J Neurooncol       Date:  2020-02-24       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.